E-Motion Medical
Solution for Restoring Digestive Motility
Company Overview
Snapshot
Founded in December 2011 by Amichay H Gross and Michael Tal MD, E-Motion Medical operates with 1–10 employees. The company develops solutions for gastrointestinal dysmotility, and its E-Motion Medicals first line of products received CE mark approval for sale in the European Union in November 2018.
Business overview
E-Motion Medical develops the E-Motion System, a proprietary technology designed to treat gastrointestinal (GI) dysmotility. This system aims to reinstate digestive motor function and enhance nutritional tolerance and safety for patients at risk of catabolism, infections, and other complications. The company serves the medical technologies sector, specifically focusing on critical care, hospitals, and clinics, with products like the E-Motion Tube and E-Motion System.
Strategic signal
In November 2018, E-Motion Medical secured CE Mark approval for its acute digestive dysmotility stimulator, enabling its products for sale in the European Union. This regulatory milestone validated the safety and efficacy of their technology, signaling market readiness and potential for commercial expansion in a significant healthcare market.
Company Intelligence Q&A
- What is E-Motion Medical's core product?
- E-Motion Medical's core product is the E-Motion System, a proprietary technology designed to treat gastrointestinal dysmotility by reinstating digestive motor function.
- When was E-Motion Medical founded?
- E-Motion Medical was founded in December 2011.
- Which regulatory approval did E-Motion Medical receive?
- In November 2018, E-Motion Medical received CE Mark approval for its acute digestive dysmotility stimulator, allowing its products to be sold in the European Union.
- Who are the co-founders of E-Motion Medical?
- E-Motion Medical was co-founded by Amichay H Gross and Michael Tal MD.
- What is the primary focus of E-Motion Medical's technology?
- E-Motion Medical's technology focuses on improving nutritional tolerance and safety for patients susceptible to catabolism, infections, and other complications by addressing GI dysmotility.